Solifenacin 5 mg
Brand names: Vesicare
Solifenacin is an antimuscarinic used to treat the urgency, frequency and urge incontinence of overactive bladder.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It blocks muscarinic (mainly M3) receptors on the bladder detrusor muscle, reducing involuntary contractions and increasing bladder capacity.
Prescribing in practice
- Avoid in narrow-angle glaucoma, significant urinary retention and gastrointestinal obstruction.
- Anticholinergic effects (dry mouth, constipation, blurred vision) are common, and it can prolong the QT interval; it may also precipitate urinary retention.
- Be mindful of the cumulative anticholinergic burden, which affects cognition and falls risk, especially in older people.
Monitoring
Review symptom benefit and anticholinergic side effects after a few weeks, watch for incomplete bladder emptying, and consider QT risk in susceptible patients.
Counselling the patient
- A dry mouth, constipation or blurred vision can occur — tell us if these bother you.
- Seek help if you find it hard or impossible to pass urine.
- If you are older, this type of medicine can affect memory or steadiness, so mention any new confusion or falls.
Evidence & guidelines
A recommended antimuscarinic option for overactive bladder in NICE guidance on urinary incontinence.
Reference: NICE NG123; STAR trial; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.